Researcher
Peter Van Dam
- Research Expertise:Translational investigations in breat and cervical cancer Immune environment in inflammatory breast cancer and cervical cancer Effect of Denosumab on the immune environment of cervical cancer Quality control of cancer treatment Telemonitoring of sidde effects of cancer treatment Cognitive impairment after cancer treatment
- Keywords:T CYTOTOXIC LYMPHOCYTE, T HELPER LYMPHOCYTE, Medicine
- Disciplines:Cancer biology, Cancer diagnosis, Cancer therapy
- Research techniques:Immunohistochemical staining Flow cytometry RNA seq
- Users of research expertise:Other interested groups
Affiliations
- Center for Oncological Research (CORE) (Research group)
Member
From1 Jan 2019 → Today - Molecular Imaging, Pathology, Radiotherapy & Oncology (MIPRO) (Research group)
Member
From1 Feb 2014 → 31 Dec 2018
Projects
1 - 10 of 10
- Establishing patient-derived organoids to rationally design therapies for patients with inflammatory breast cancerFrom1 Nov 2023 → TodayFunding: Nonprofit institution or equivalents
- Reinvigorating the antitumor immunity in human breastand cervical cancer with an innovative RANK(L) targeted combination strategy.From1 Nov 2021 → TodayFunding: Nonprofit institution or equivalents
- Development and validation of a novel rationally designed immunotherapeutic combination strategy built upon targeting RANK(L) for cervical cancer.From1 Nov 2020 → TodayFunding: FWO Strategic Basic Research Grant
- Acquired immunity and immunologic aspects of SARS-CoV-2 infection a population of patients and healthcare workers in Multidisciplinary Oncologic Centres. (MOCOR-Study).From1 Jun 2020 → 31 May 2021Funding: BOF - projects
- Unveiling the drug repurposing versatility of denosumab in the battle against human cervical cancer.From1 Jan 2020 → 31 Dec 2020Funding: Nonprofit institution or equivalents
- Integrated Personalized & Precision Oncology Network (IPPON).From1 Jan 2020 → TodayFunding: BOF - research organisations, Fund Recuperation Fiscal Exemption
- The role of infiltrating immune cells in the aggresive phenotype of inflammatory breast cancer and possible new (immuno)therapeutic targets.From1 Oct 2018 → 30 Sep 2020Funding: FWO fellowships
- RANK signaling and checkpoint inhibition.From15 Sep 2018 → 14 Sep 2021Funding: Nonprofit institution or equivalents
- The role of infiltrating immune cells in the aggresive phenotype of inflammatory breast cancer and possible new (immuno)therapeutic targets.From1 Oct 2016 → 30 Sep 2018Funding: FWO fellowships
- Characterization of the stromal component in inflammatory breast cancer.From15 Jan 2016 → 14 Jan 2017Funding: Nonprofit institution or equivalents
Publications
31 - 40 of 108
- Meeting the challenges in cancer care management during the SARS-Cov-2 pandemic(2021)
Authors: Marika Rasschaert, Pieterjan Vanclooster, Laura Depauw, Tim Mertens, Ella Roelant, Elke Coenen, Sébastien Anguille, Annelies J R Janssens, Peter Van Dam, Marc Peeters
- Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment(2021)
Authors: Marc Peeters, L. Verbruggen, Laure-Anne Teuwen, Greetje Vanhoutte, S. Vande Kerckhove, Sanne Raats, I. Van der Massen, Yana Debie, M. Huizing, P. Pannus, et al.
- Immunoglobin G/total antibody testing for SARS-CoV-2(2021)
Authors: Peter Van Dam, Manon Huizing, Ella Roelant, An Hotterbeekx, Fien De Winter, Samir Kumar-Singh, Pieter Moons, Zainab Amajoud, Christof Vulsteke, Lieselot Croes, et al.
Pages: 328 - 339 - A high neutrophil-lymphocyte ratio and platelet-lymphocyte ratio are associated with a worse outcome in inflammatory breast cancer(2020)
Authors: Christophe Van Berckelaer, M. Van Geyt, S. Linders, Charlotte Rypens, Xuan Bich Trinh, Wiebren Tjalma, Steven Van Laere, Cecile Colpaert, Luc Dirix, Peter Van Dam
Pages: 212 - 220 - The non-bone-related role of RANK/RANKL signaling in cancer(2020)
Authors: Peter Van Dam, Yannick Verhoeven, Xuan Bich Trinh
Pages: 53 - 62 - Central radiology assessment of the randomized phase III open-label OVHIPEC-1 trial in ovarian cancer(2020)
Authors: Simone N. Koole, Leigh Bruijs, Cristina Fabris, Karolina Sikorska, Maurits Engbersen, Jules H. Schagen van Leeuwen, Henk W.R. Schreuder, Ralph H. Hermans, Jacobus van der Velden, Henriette J.G. Arts, et al.
Pages: 1928 - 1934 - Inflammatory breast cancer cells are characterized by abrogated TGFβ1-dependent cell motility and SMAD3 activity(2020)
Authors: Charlotte Rypens, Melike Marsan, Christophe Van Berckelaer, Kirsten Melis, Sara Perez Lopez, Peter Van Dam, Gayathri R. Devi, Pascal Finetti, Naoto T. Ueno, François Bertucci, et al.
Pages: 385 - 395 - Acceptability of quality indicators for the management of endometrial, cervical and ovarian cancer: results of an online survey(2020)
Authors: Annemie Luyckx, Leen Wyckmans, Anne-Sophie Bonte, Xuan Bich Trinh, Peter Van Dam
- HIPEC in advanced epithelial ovarian cancer(2020)
Authors: Jan Vermorken, Peter Van Dam, Alison Brand
Pages: 451 - 458 - Triple-negative breast cancer(2020)
Authors: Gizem Oner, Sevilay Altintas, Zafer Canturk, Wiebren Tjalma, Yannick Verhoeven, Christophe Van Berckelaer, Zwi Berneman, Marc Peeters, Patrick Pauwels, Peter Van Dam
Pages: 995 - 999